--- title: "Non-Dilutive Funding, Definition | MedTech Terms" description: "Capital that does not require giving up equity, such as grants or debt. Plain-English Investment & Finance definition for MedTech teams, with examples and relat" lang: en json-ld: | { "@context": "https://schema.org", "@graph": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/non-dilutive-funding#term", "name": "Non-Dilutive Funding", "description": "Non-dilutive funding includes government grants (NIH SBIR/STTR, BARDA, ARPA-H), foundation grants, venture debt, revenue-based financing, and strategic milestone payments - capital that does not require issuing equity.", "url": "https://medtechterms.com/terms/non-dilutive-funding", "termCode": "non-dilutive-funding", "inDefinedTermSet": { "@type": "DefinedTermSet", "name": "MedTech Terms", "url": "https://medtechterms.com/terms" } }, { "@type": "Article", "@id": "https://medtechterms.com/terms/non-dilutive-funding#article", "headline": "Non-Dilutive Funding", "description": "Capital that does not require giving up equity, such as grants or debt.", "url": "https://medtechterms.com/terms/non-dilutive-funding", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://medtechterms.com/terms/non-dilutive-funding" }, "about": { "@id": "https://medtechterms.com/terms/non-dilutive-funding#term" }, "articleSection": "Investment & Finance", "inLanguage": "en", "keywords": "Non-Dilutive Funding, Investment & Finance, medical device, MedTech", "author": { "@type": "Person", "name": "Christian Espinosa", "jobTitle": "Founder, Blue Goat Cyber", "url": "https://bluegoatcyber.com" }, "publisher": { "@type": "Organization", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "isPartOf": { "@type": "WebSite", "name": "MedTech Terms", "url": "https://medtechterms.com" }, "datePublished": "2026-05-05", "dateModified": "2026-05-05", "citation": [ { "@type": "CreativeWork", "name": "NIH SBIR/STTR", "url": "https://seed.nih.gov/", "publisher": { "@type": "Organization", "name": "NIH" } }, { "@type": "CreativeWork", "name": "Silicon Valley Bank - Healthcare Reports", "url": "https://www.svb.com/trends-insights/", "publisher": { "@type": "Organization", "name": "SVB" } }, { "@type": "CreativeWork", "name": "PitchBook - MedTech Coverage", "url": "https://pitchbook.com/news/articles/topic/healthtech", "publisher": { "@type": "Organization", "name": "PitchBook" } } ], "mentions": [ { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/sbir-sttr#term", "name": "SBIR / STTR Grants", "alternateName": "SBIR/STTR", "url": "https://medtechterms.com/terms/sbir-sttr" }, { "@type": "DefinedTerm", "@id": "https://medtechterms.com/terms/venture-debt#term", "name": "Venture Debt", "url": "https://medtechterms.com/terms/venture-debt" } ] }, { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://medtechterms.com/" }, { "@type": "ListItem", "position": 2, "name": "Terms", "item": "https://medtechterms.com/terms" }, { "@type": "ListItem", "position": 3, "name": "Investment & Finance", "item": "https://medtechterms.com/terms?cat=Investment%20%26%20Finance" }, { "@type": "ListItem", "position": 4, "name": "Non-Dilutive Funding", "item": "https://medtechterms.com/terms/non-dilutive-funding" } ] }, { "@type": "FAQPage", "@id": "https://medtechterms.com/terms/non-dilutive-funding#faq", "mainEntity": [ { "@type": "Question", "name": "Does non-dilutive funding affect regulatory submissions?", "acceptedAnswer": { "@type": "Answer", "text": "The source of funding generally does not directly impact the content or review process of regulatory submissions, such as FDA 510(k) or PMA applications. However, strong financial backing, regardless of source, can demonstrate a company's ability to support post-market surveillance and other regulatory obligations." } }, { "@type": "Question", "name": "Are there specific quality system implications for projects funded through non-dilutive means?", "acceptedAnswer": { "@type": "Answer", "text": "No, the quality system requirements, such as those outlined in FDA 21 CFR 820 or ISO 13485:2016, apply equally to all MedTech development projects, regardless of their funding source. Companies must maintain a robust quality management system to ensure product safety and effectiveness." } }, { "@type": "Question", "name": "Can non-dilutive funding influence cybersecurity considerations for MedTech devices?", "acceptedAnswer": { "@type": "Answer", "text": "Indirectly, adequate non-dilutive funding can enable a MedTech company to invest sufficiently in cybersecurity measures, including those recommended by FDA guidance on premarket and postmarket cybersecurity management. This ensures resources are available for robust security development and maintenance." } } ] } ] } --- [ MedTech Terms The authoritative reference ](/) Browse Learn [Latest](/latest) About 1. [Home](/) 2. / 3. [Terms](/terms) 4. / 5. [Investment & Finance](/terms?cat=Investment%20%26%20Finance) 6. / 7. Non-Dilutive Funding [All terms](/terms) Investment & Finance [Startup Lifecycle](/ecosystems/startup-lifecycle) # Non-Dilutive Funding Capital that does not require giving up equity, such as grants or debt. Reviewed by [Christian Espinosa, Founder, Blue Goat Cyber](/authors/christian-espinosa) Last reviewed May 5, 2026 ## Definition Non-dilutive funding includes government grants (NIH [SBIR/STTR](/terms/sbir-sttr), BARDA, ARPA-H), foundation grants, [venture debt](/terms/venture-debt), [revenue-based financing](/terms/royalty-financing), and strategic milestone payments - capital that does not require issuing equity. What the regulation says While non-dilutive funding itself is not directly regulated, the use of such funds in MedTech is subject to the same regulatory requirements as any other funding source (e.g., FDA 21 CFR Part 820 for [Quality System Regulation](/terms/qsr)). Funding from government sources like NIH or BARDA often comes with specific reporting and compliance obligations related to project milestones and expenditures, distinct from general MedTech regulations. ## What this means in practice SBIR Phase I/II grants are a common MedTech bridge from idea to first equity round. [Venture debt](/terms/venture-debt) typically arrives after a [Series B](/terms/series-funding) and extends [runway](/terms/runway) with minimal [dilution](/terms/dilution). ## Examples - A MedTech startup receives an NIH SBIR grant to develop a novel diagnostic algorithm, which allows them to fund early-stage research and development without giving up equity before seeking venture capital. - A mature medical device company uses venture debt to expand its manufacturing capabilities for an existing Class II device, avoiding shareholder dilution while meeting increased market demand. - A small MedTech firm secures a BARDA contract to accelerate the development of a therapeutic device for pandemic preparedness, ensuring rapid prototyping and clinical trials without immediate equity financing. Common pitfalls - • Confusing non-dilutive funding with a lack of financial oversight, as all financial activities within a MedTech company are subject to scrutiny during audits. - • Underestimating the administrative burden and reporting requirements associated with government grants, which can divert resources from core MedTech development activities. - • Failing to allocate non-dilutive funds appropriately to ensure compliance with quality system requirements (e.g., ISO 13485) throughout the product lifecycle. - • Assuming that non-dilutive funding implies less scrutiny on the scientific or technical merit of the MedTech innovation, as these funds often have rigorous review processes. ## Frequently asked questions Does non-dilutive funding affect regulatory submissions? The source of funding generally does not directly impact the content or review process of regulatory submissions, such as FDA 510(k) or [PMA](/terms/pma) applications. However, strong financial backing, regardless of source, can demonstrate a company's ability to support [post-market surveillance](/terms/post-market-surveillance) and other regulatory obligations. Are there specific quality system implications for projects funded through non-dilutive means? Can non-dilutive funding influence cybersecurity considerations for MedTech devices? ## Related terms Grouped by theme ### Editor's picks · Hand-selected related concepts [ Investment & Finance SBIR / STTR Grants(SBIR/STTR) U.S. federal small-business R&D grants from agencies including NIH and DoD. ](/terms/sbir-sttr)[ Investment & Finance Venture Debt Loan made to a venture-backed company, usually alongside or after equity. ](/terms/venture-debt) ### More in Investment & Finance · Same category [ Investment & Finance 409A Valuation An independent fair-market-value appraisal of common stock used to set tax-compliant strike prices for employee stock options. ](/terms/409a-valuation)[ Investment & Finance Anti-Dilution Protection Adjustment that protects investors if the company raises a future round at a lower price. ](/terms/anti-dilution)[ Investment & Finance Bridge Round Interim financing between priced rounds, usually convertible. ](/terms/bridge-round)[ Investment & Finance Burn Rate Rate at which a company spends cash, typically expressed monthly. ](/terms/burn-rate) Cited by Where this term appears across MedTech Terms. Ecosystems (1) - [Startup Lifecycle](/ecosystems/startup-lifecycle) ## Primary references 3 sources Link health: 3 verified · last checked 2026-06-20 NIH· 1 SVB· 1 PitchBook· 1 1. [1 NIH SBIR/STTR Verified NIH · seed.nih.gov ](https://seed.nih.gov/) 2. [2 Silicon Valley Bank - Healthcare Reports Verified SVB · svb.com ](https://www.svb.com/trends-insights/) 3. [3 PitchBook - MedTech Coverage Verified PitchBook · pitchbook.com ](https://pitchbook.com/news/articles/topic/healthtech) Inline markers like \[1\] jump to the matching reference above. Sponsor note ### Diligencing a MedTech cybersecurity posture? Blue Goat Cyber supports investors and acquirers with cybersecurity diligence on connected MedTech assets. [Book a 30-minute discovery session](https://go.bluegoatcyber.com/meetings/blue-goat-cyber/discovery-session) - No obligation - Expert-led from minute one - NDA available on request MedTech Terms is a community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com). Definitions are independent of any vendor. On this term Category Investment & Finance Sources 3 Updated 5/5/2026 [Compare with another term](/compare?a=non-dilutive-funding) Learn in 60 seconds Card Lesson Quiz Capital that does not require giving up equity, such as grants or debt. - · SBIR Phase I/II grants are a common MedTech bridge from idea to first equity round. - · Venture debt typically arrives after a Series B and extends runway with minimal dilution. Remember this Watch out: Confusing non-dilutive funding with a lack of financial oversight, as all financial activities within a MedTech company are subject to scrutiny during audits. Related terms - [SBIR / STTR Grants(SBIR/STTR) ](/terms/sbir-sttr) - [Venture Debt ](/terms/venture-debt) You may also need Auto-suggested from Investment & Finance and shared keywords. - [Royalty Financing ](/terms/royalty-financing) - [Milestone Payment ](/terms/milestone-payment) - [Convertible Note ](/terms/convertible-note) - [Earn-Out ](/terms/earn-out) - [Initial Public Offering(IPO) ](/terms/ipo) - [Series A / B / C Financing Rounds ](/terms/series-funding) [All Investment & Finance terms](/terms?cat=Investment%20%26%20Finance) MedTech Terms An authoritative, plain-language reference for the regulatory, quality, cybersecurity, and software terms that shape modern medical devices. Browse - [All terms](/terms) - [A–Z index](/a-z) - [Categories](/categories) - [Ecosystems](/ecosystems) - [Learning paths](/paths) - [Compare terms](/compare) - [Quiz](/quiz) Resources - [FDA Medical Devices](https://www.fda.gov/medical-devices) - [EU MDR](https://eur-lex.europa.eu/eli/reg/2017/745/oj) - [IMDRF](https://www.imdrf.org/) - [Methodology](/methodology) - [Changelog](/changelog) - [Editor: Christian Espinosa](/authors/christian-espinosa) - [About this site](/about) © 2026 MedTech Terms. Reference content for educational purposes - not regulatory advice. A community resource sponsored by [Blue Goat Cyber](https://bluegoatcyber.com)